PRLDHIGH SIGNALFINANCIAL10-K

PRLD shows dramatically improved operating performance with reduced losses and increased revenue, but concerning balance sheet deterioration including a 48% decline in stockholders' equity and doubling of liabilities.

The company appears to be at an inflection point with meaningfully improved operational efficiency (45% better operating cash flow, 22% reduction in net losses) suggesting better expense management or pipeline progress. However, the severe equity decline combined with doubled current liabilities raises immediate liquidity and financial stability concerns that could constrain future operations.

Comparing 2026-03-10 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

PRLD delivered strong operational improvements with 73% revenue growth and significantly reduced losses across all profitability metrics, while dramatically cutting capital expenditures by 91%. However, the balance sheet shows severe stress with stockholders' equity falling 48% to $68.6M, current liabilities more than doubling to $53M, and current assets declining 22%, creating a concerning mismatch between improving operations and deteriorating financial position. Despite higher cash levels, the overall financial picture suggests potential liquidity pressures that could threaten the company's ability to fund ongoing operations and clinical development programs.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+182.6%
$12.5M$35.3M

Cash position surged 182.6% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
+106.7%
$25.6M$53.0M

Current liabilities surged 106.7% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-91.2%
$764K$67K

Capex reduced 91.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Revenue
P&L
+73.4%
$7.0M$12.1M

Strong top-line growth of 73.4% — accelerating demand or successful expansion into new markets.

Total Liabilities
Balance Sheet
+65%
$44.1M$72.7M

Liabilities grew 65% — significant increase in debt or obligations, assess impact on financial flexibility.

Stockholders Equity
Balance Sheet
-47.8%
$131.5M$68.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
+45.3%
-$102.9M-$56.3M

Operating cash flow surged 45.3% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+25.2%
-$139.7M-$104.6M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Assets
Balance Sheet
-22.2%
$135.9M$105.7M

Current assets declined 22.2% — monitor working capital adequacy and short-term liquidity.

Net Income
P&L
+21.8%
-$127.2M-$99.5M

Net income grew 21.8% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-10
ADDED
Our discovery excellence has been supported by our steady progress in advancing a pipeline of novel precision oncology development candidates, alone and with partners.
We believe we can best address these diseases by harnessing advances in new therapeutic modalities such as targeted protein degradation to develop highly potent and specific agents against clinically validated targets in areas of high unmet need.
Identify target mechanisms with a compelling biological rationale o Current target mechanisms of focus include transcriptional regulation and uncontrolled cell proliferation signaling mediated by well characterized driver mutations.
Leverage our advanced medicinal chemistry capabilities to create better product candidates o We leverage multiple modalities (inhibitors, degraders, and antibody-drug conjugates) in order to deliver clinical candidates that meet our desired target product profiles.
By focusing on what we believe are clinically validated targets with a clear path to differentiation and early clinical proof-of-concept, we seek to advance our programs through expedited approval processes, as available.
+7 more — sign up free →
REMOVED
Our discovery excellence has been supported by our steady progress in creating a wholly owned, internally developed pipeline.
We also began work with our partner AbCellera Biologics, Inc.
We believe we can best address these diseases by developing therapies that target primary and secondary resistance mechanisms.
Identify target mechanisms with a compelling biological rationale o Current target mechanisms of focus include transcriptional regulation, deoxyribonucleic acid, or DNA, repair pathway, cell cycle regulation, exploitation of synthetic lethality and brain penetrant molecules.
Leverage our advanced medicinal chemistry capabilities to create better product candidates o We view all target classes equally and strive to invent clinical candidates that meet our desired target product profiles.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →